We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+3.66%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$7.51B
AUM Growth
-$1.07B
Cap. Flow
-$907M
Cap. Flow %
-12.08%
Top 10 Hldgs %
65.31%
Holding
49
New
3
Increased
11
Reduced
9
Closed
8

Top Buys

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$36.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$31.3M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$26.4M
4
MRUS
Merus
MRUS
+$22.6M
5
SLNO
Soleno Therapeutics
SLNO
+$19.8M

Top Sells

Rank Stock Value
1
VKTX icon
Viking Therapeutics
VKTX
+$294M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$229M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$173M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$113M
5
MGNX icon
MacroGenics
MGNX
+$90.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
26
Ocular Therapeutix
OCUL
$1.92B
$55.1M 0.73%
8,060,000
+911,064
+13% +$5.62M
MNKD icon
27
MannKind Corp
MNKD
$1.24B
$45.7M 0.61%
8,759,524
-240,476
-3% -$1.09M
PCVX icon
28
Vaxcyte
PCVX
$8.37B
$43.4M 0.58%
575,000
– –
SYRE icon
29
Spyre Therapeutics
SYRE
$9.16B
$43.2M 0.58%
1,839,138
– –
AUTL
30
Autolus Therapeutics
AUTL
$516M
$43M 0.57%
12,345,678
– –
TSHA icon
31
Taysha Gene Therapies
TSHA
$1.83B
$41.8M 0.56%
18,650,000
– –
RARE icon
32
Ultragenyx Pharmaceutical
RARE
$2.52B
$34.1M 0.45%
830,000
– –
VRCA icon
33
Verrica Pharmaceuticals
VRCA
$93.6M
$29.2M 0.39%
400,000
– –
TRML
34
DELISTED
Tourmaline Bio
TRML
$28.6M 0.38%
2,222,222
– –
CGON icon
35
CG Oncology
CGON
$6.57B
$22.1M 0.29%
700,000
– –
GLUE icon
36
Monte Rosa Therapeutics
GLUE
$1.34B
$17M 0.23%
4,535,000
– –
BCYC
37
Bicycle Therapeutics
BCYC
$277M
$14.2M 0.19%
+700,000
New +$15.8M
WHWK
38
Whitehawk Therapeutics
WHWK
$226M
$4.16M 0.06%
2,849,402
– –
DYN icon
39
Dyne Therapeutics
DYN
$4.81B
$4.08M 0.05%
+115,751
New +$3.36M
ADVM
40
DELISTED
Adverum Biotechnologies
ADVM
$2.86M 0.04%
416,666
– –
NGNE icon
41
Neurogene
NGNE
$712M
$802K 0.01%
+22,029
New +$777K
CRSP icon
42
CRISPR Therapeutics
CRSP
$5.05B
– –
-419,580
Closed -$28.6M
MGNX icon
43
MacroGenics
MGNX
$248M
– –
-6,150,000
Closed -$90.5M
RCKT icon
44
Rocket Pharmaceuticals
RCKT
$389M
– –
-1,260,900
Closed -$34M
ROIV icon
45
Roivant Sciences
ROIV
$25.3B
– –
-4,651,162
Closed -$49M
VKTX icon
46
Viking Therapeutics
VKTX
$3.88B
– –
-3,590,000
Closed -$294M
KYTX icon
47
Kyverna Therapeutics
KYTX
$474M
– –
-475,000
Closed -$11.8M
ALPN
48
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-5,775,000
Closed -$229M
MRNS
49
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-4,140,607
Closed -$37.4M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Avoro Capital Advisors held 49 positions worth $7.51B, down 12% from $8.57B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Avoro Capital Advisors withdrew a net $907M in Q2 2024, closing 8 positions and reducing 9 holdings. Its most notable exit was Viking Therapeutics, an estimated $294M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in Bicycle Therapeutics worth $14.2M.

  • Avoro Capital Advisors's largest Q2 2024 buy was Bicycle Therapeutics: 700,000 shares worth $14.2M.
  • Avoro Capital Advisors added most to Intra-Cellular Therapies Inc. in Q2 2024, an estimated $36.4M increase.
  • Avoro Capital Advisors's biggest Q2 2024 reduction was Sarepta Therapeutics, cutting an estimated $173M.
  • Avoro Capital Advisors fully exited Viking Therapeutics in Q2 2024, selling an estimated $294M.
  • Avoro Capital Advisors's ten largest holdings make up 65% of its $7.51B portfolio in Q2 2024.
  • Avoro Capital Advisors opened 3 new positions and closed 8 in Q2 2024.
  • Avoro Capital Advisors's portfolio value fell 12% quarter-over-quarter to $7.51B.

Based on Avoro Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.